ARGENX SE(EBR:ARGX) stock Fundamental Analysis

Fundamental Rating

We assign a fundamental rating of 5 out of 10 to ARGX. ARGX was compared to 71 industry peers in the Biotechnology industry. While ARGX seems to be doing ok healthwise, there are quite some concerns on its profitability. ARGX is valued quite expensive, but it does show an excellent growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

ARGX had positive earnings in the past year.

In the past year ARGX has reported a negative cash flow from operations.

ARGX had negative earnings in 4 of the past 5 years.

ARGX had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

ARGX's Return On Assets of 13.41% is amongst the best of the industry. ARGX outperforms 92.96% of its industry peers.

ARGX has a better Return On Equity (15.13%) than 84.51% of its industry peers.

		Industry Rank	Sector Rank
ROA	13.41%
ROE	15.13%
ROIC	N/A

ROA(3y)-5.24%

ROA(5y)-11.34%

ROE(3y)-5.76%

ROE(5y)-13.94%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

With an excellent Profit Margin value of 37.99%, ARGX belongs to the best of the industry, outperforming 94.37% of the companies in the same industry.

Looking at the Gross Margin, with a value of 89.63%, ARGX belongs to the top of the industry, outperforming 90.14% of the companies in the same industry.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	37.99%
GM	89.63%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ARGX does not have a ROIC to compare to the WACC, probably because it is not profitable.

ARGX has more shares outstanding than it did 1 year ago.

ARGX has more shares outstanding than it did 5 years ago.

ARGX has a worse debt/assets ratio than last year.

2.2 Solvency

An Altman-Z score of 31.42 indicates that ARGX is not in any danger for bankruptcy at the moment.

ARGX's Altman-Z score of 31.42 is amongst the best of the industry. ARGX outperforms 98.59% of its industry peers.

ARGX has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.

ARGX has a Debt to Equity ratio of 0.01. This is amongst the best in the industry. ARGX outperforms 87.32% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.01
Debt/FCF	N/A
Altman-Z	31.42

ROIC/WACCN/A

WACC7.57%

2.3 Liquidity

A Current Ratio of 7.29 indicates that ARGX has no problem at all paying its short term obligations.

Looking at the Current ratio, with a value of 7.29, ARGX belongs to the top of the industry, outperforming 90.14% of the companies in the same industry.

ARGX has a Quick Ratio of 6.68. This indicates that ARGX is financially healthy and has no problem in meeting its short term obligations.

ARGX has a better Quick ratio (6.68) than 88.73% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	7.29
Quick Ratio	6.68

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 194.52% over the past year.

The Revenue has grown by 78.63% in the past year. This is a very strong growth!

ARGX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 94.61% yearly.

EPS 1Y (TTM)194.52%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%348.08%

Revenue 1Y (TTM)78.63%

Revenue growth 3Y63.91%

Revenue growth 5Y94.61%

Sales Q2Q%95.72%

3.2 Future

Based on estimates for the next years, ARGX will show a very strong growth in Earnings Per Share. The EPS will grow by 106.31% on average per year.

ARGX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 31.13% yearly.

EPS Next Y576.65%

EPS Next 2Y242.7%

EPS Next 3Y155.24%

EPS Next 5Y106.31%

Revenue Next Year64.81%

Revenue Next 2Y47.5%

Revenue Next 3Y39.17%

Revenue Next 5Y31.13%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 108.79, the valuation of ARGX can be described as expensive.

ARGX's Price/Earnings ratio is a bit cheaper when compared to the industry. ARGX is cheaper than 76.06% of the companies in the same industry.

When comparing the Price/Earnings ratio of ARGX to the average of the S&P500 Index (25.82), we can say ARGX is valued expensively.

ARGX is valuated quite expensively with a Price/Forward Earnings ratio of 28.64.

Based on the Price/Forward Earnings ratio, ARGX is valued cheaper than 80.28% of the companies in the same industry.

ARGX is valuated rather expensively when we compare the Price/Forward Earnings ratio to 21.76, which is the current average of the S&P500 Index.

		Industry Rank	Sector Rank
PE	108.79
Fwd PE	28.64

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.

A more expensive valuation may be justified as ARGX's earnings are expected to grow with 155.24% in the coming years.

PEG (NY)0.19

PEG (5Y)N/A

EPS Next 2Y242.7%

EPS Next 3Y155.24%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

ARGX does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

ARGENX SE

EBR:ARGX (5/23/2025, 7:00:00 PM)

514.6

-1.8 (-0.35%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)05-08 2025-05-08/bmo

Earnings (Next)07-31 2025-07-31/bmo

Inst Owners39.35%

Inst Owner ChangeN/A

Ins Owners0.12%

Ins Owner ChangeN/A

Market Cap31.42B

Analysts84.62

Price Target699 (35.83%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)1

Avg EPS beat(2)7909.56%

Min EPS beat(2)-38.07%

Max EPS beat(2)15857.2%

EPS beat(4)2

Avg EPS beat(4)3984.41%

Min EPS beat(4)-38.07%

Max EPS beat(4)15857.2%

EPS beat(8)5

Avg EPS beat(8)2003.12%

EPS beat(12)8

Avg EPS beat(12)1344.81%

EPS beat(16)12

Avg EPS beat(16)1027.8%

Revenue beat(2)2

Avg Revenue beat(2)6.37%

Min Revenue beat(2)5.75%

Max Revenue beat(2)6.99%

Revenue beat(4)3

Avg Revenue beat(4)5.41%

Min Revenue beat(4)-0.25%

Max Revenue beat(4)9.17%

Revenue beat(8)7

Avg Revenue beat(8)7.53%

Revenue beat(12)11

Avg Revenue beat(12)27.61%

Revenue beat(16)14

Avg Revenue beat(16)43.67%

PT rev (1m)-0.88%

PT rev (3m)7.77%

EPS NQ rev (1m)0%

EPS NQ rev (3m)26.38%

EPS NY rev (1m)0%

EPS NY rev (3m)14.53%

Revenue NQ rev (1m)0.56%

Revenue NQ rev (3m)7.84%

Revenue NY rev (1m)2.4%

Revenue NY rev (3m)6.54%

Valuation

		Industry Rank	Sector Rank
PE	108.79
Fwd PE	28.64
P/S	16.23
P/FCF	N/A
P/OCF	N/A
P/B	6.46
P/tB	6.68
EV/EBITDA	N/A

EPS(TTM)4.73

EY0.92%

EPS(NY)17.97

Fwd EY3.49%

FCF(TTM)-2.19

FCFYN/A

OCF(TTM)-1.2

OCFYN/A

SpS31.72

BVpS79.64

TBVpS77.01

PEG (NY)0.19

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	13.41%
ROE	15.13%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	37.99%
GM	89.63%
FCFM	N/A

ROA(3y)-5.24%

ROA(5y)-11.34%

ROE(3y)-5.76%

ROE(5y)-13.94%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score2

Asset Turnover0.35

Health

		Industry Rank	Sector Rank
Debt/Equity	0.01
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	937.93%
Cap/Sales	3.11%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	7.29
Quick Ratio	6.68
Altman-Z	31.42

F-Score2

WACC7.57%

ROIC/WACCN/A

Cap/Depr(3y)606.32%

Cap/Depr(5y)803.99%

Cap/Sales(3y)10.66%

Cap/Sales(5y)13.77%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)194.52%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%348.08%

EPS Next Y576.65%

EPS Next 2Y242.7%

EPS Next 3Y155.24%

EPS Next 5Y106.31%

Revenue 1Y (TTM)78.63%

Revenue growth 3Y63.91%

Revenue growth 5Y94.61%

Sales Q2Q%95.72%

Revenue Next Year64.81%

Revenue Next 2Y47.5%

Revenue Next 3Y39.17%

Revenue Next 5Y31.13%

EBIT growth 1Y96.52%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year959.92%

EBIT Next 3Y190.57%

EBIT Next 5Y115.14%

FCF growth 1Y67.46%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y80.24%

OCF growth 3YN/A

OCF growth 5YN/A

ARGENX SE (ARGX.BR) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens